Patent Assignment
Reel/Frame 030057/0633
Change of Name
Recorded: 2013-03-21
Pages: 28
Assignor
NYCOMED GMBH
Executed: 2012-11-14
Assignee
TAKEDA GMBH
BYK-GULDEN-STRASSE 2, KONSTANZ, 78467, GERMANY
Covered Properties
(32)
Salt of (S)-Pantoprazole and Its Hydrates
Ophthalmological use of roflumilast for the treatment of diseases of the eye
Application:
10/515,896 →
Publication:
US 2006/0084685
Ciclesonide-Containing Sterile Aqueous Suspension
Pyrrolidinedione Substituted Piperidine-Phthalazones as PDE4 Inhibitors
3-Hydroxy-6-Phenylphenanthridines as Pde-4 Inhibitors
Use of the Combination of Ciclesonide and Antihistamines for the Treatment of Allergic Rhinitis
Process for Preparing Optically Pure Active Compounds
Process for Preparing (S)-Pantoprazole
Combination Medicament
Formoterol and Ciclesonide Combination
Composition Comprising a Pulmonary Surfactant and a PDE5 Inhibitor for the Treatment of Lung Diseases
Use of ciclesonide for the treatment of inflammatory bowel diseases
Application:
10/570,986 →
Publication:
US 2006/0211668
Use of Ciclesonide for the Treatment of Respiratory Diseases
Compliance monitor and method
Novel Medicine Pack
Aqueous suspensions of ciclesonide for nebulisation
Application:
10/582,499 →
Publication:
US 2007/0117783
2-(Piperidin-4-Yl)-4,5-Dihydro-2H-Pyridazin-3-One Derivatives as PDE4 Inhibitors
Novel Guanidinyl-Substituted Hydroxy-6-Phenylphenanthridines as Effective Phosphodiesterase (Pde) 4 Inhibitors
Novel Use for PDE5 Inhibitors
Use of Ciclesonide for the Treatment of Respiratory Diseases in a Smoking Patient
Application:
11/578,294 →
Publication:
US 2007/0134165
Triazolophthalazines
3-Hydroxy-6-Phenylphenanthridines as PDE4 Inhibitors
2-(Piperidin-4-Yl)-4,5-Dihydro-2H-Pyridazin-3-One Derivatives as PDE4 Inhibitors
Dosage form containing pantoprazole as active ingredient
Novel Guanidinyl-Substituted Hydroxy-6-Phenylphenanthridines
Ciclesonide-Containing Sterile Aqueous Suspension
Novel Use for PDE5 Inhibitors
Combination Medicament
Use of the Combination of Ciclesonide and Antihistamines for the Treatment of Allergic Rhinitis
Dosage Form Containing (S)-Pantoprazole as Active Ingredient
Pharmaceutical Product for Injection
Application:
13/273,337 →
Publication:
US 2012/0083512
Composition Comprising a PDE4 Inhibitor and a PDE5 Inhibitor
Application:
13/445,675 →
Publication:
US 2012/0196867
Related Assignments
(24)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Jun 28, 2006
From: BRUECK-SCHEFFLER, ANTJE
To: ALTANA PHARMA AG
Reel/Frame 017873/0573 →
Change of Name
Sep 4, 2007
From: ALTANA PHARMA AG
To: NYCOMED GMBH
Reel/Frame 019783/0625 →
Change of Name
Sep 4, 2007
From: ALTANA PHARMA AG
To: NYCOMED GMBH
Reel/Frame 019781/0225 →
Change of Name
Oct 10, 2008
From: ALTANA PHARMA AG
To: NYCOMED GMBH
Reel/Frame 021669/0109 →
Merger
Jul 28, 2015
From: TAKEDA GMBH
To: NYCOMED ASSET MANAGEMENT GMBH
Reel/Frame 036193/0224 →
Merger
Jul 28, 2015
From: NYCOMED ASSET MANAGEMENT GMBH
To: NYCOMED GERMANY HOLDING GMBH
Reel/Frame 036201/0478 →
Merger
Jul 28, 2015
From: TAKEDA GMBH
To: NYCOMED ASSET MANAGEMENT GMBH
Reel/Frame 036193/0178 →
Merger
Jul 28, 2015
From: NYCOMED ASSET MANAGEMENT GMBH
To: NYCOMED GERMANY HOLDING GMBH
Reel/Frame 036201/0261 →
Change of Name
Jul 29, 2015
From: NYCOMED GERMANY HOLDING GMBH
To: TAKEDA GMBH
Reel/Frame 036205/0179 →
Change of Name
Jul 29, 2015
From: NYCOMED GERMANY HOLDING GMBH
To: TAKEDA GMBH
Reel/Frame 036205/0192 →
Assignment of Assignor's Interest
Jan 11, 2017
From: TAKEDA GMBH
To: ASTRAZENECA AB
Reel/Frame 041328/0362 →
Assignment of Assignor's Interest
Dec 10, 2018
From: ASTRAZENECA AB
To: COVIS PHARMA B.V.
Reel/Frame 047761/0435 →
Security Interest
Dec 20, 2018
From: COVIS PHARMA B.V.
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 047834/0926 →
Security Interest
Mar 12, 2020
From: COVIS PHARMA B.V.
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 052095/0262 →
Release of Security Interest
Mar 17, 2020
From: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: COVIS PHARMA B.V.
Reel/Frame 052142/0961 →
Business Transfer and Contribution Agreement
Dec 16, 2020
From: COVIS PHARMA B.V.
To: COVIS PHARMA GMBH
Reel/Frame 054793/0416 →
Security Interest
Feb 22, 2021
From: COVIS PHARMA GMBH
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 055354/0063 →
Notice of Grant of Security Interest in Intellectual Property (First Lien)
Jan 4, 2022
From: COVIS PHARMA GMBH
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 058640/0787 →
Notice of Grant of Security Interest in Intellectual Property (Second Lien)
Feb 18, 2022
From: COVIS PHARMA GMBH
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 059232/0514 →
Release of Security Interest
Feb 18, 2022
From: CAPITAL ONE, NATIONAL ASSOCIATION
To: COVIS PHARMA GMBH
Reel/Frame 059043/0226 →
Release of Security Interest
Feb 18, 2022
From: CAPITAL ONE, NATIONAL ASSOCIATION
To: COVIS PHARMA B.V.
Reel/Frame 059043/0239 →
Release of Security Interest
Jun 2, 2023
From: BARCLAYS BANK PLC
To: COVIS PHARMA GMBH
Reel/Frame 063841/0208 →
Release of Security Interest in Patents
Mar 17, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
To: COVIS PHARMA GMBH
Reel/Frame 070537/0122 →
Confirmatory Grant of Security Interest in United States Patents
May 27, 2025
From: COVIS PHARMA GBMH
To: HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 071409/0368 →